Validation analysis of a composite real‐world mortality endpoint for patients with cancer in the United States

Abstract

Objective We expanded the previous assessment of a mortality variable suited for real‐world evidence‐focused oncology research. Data source We used a nationwide electronic health record (EHR)‐derived de‐identified database. Data collection We included patients with at least 1 of 18 cancer types between January 1, 2011 and December 31, 2017. Patient‐level structured data (EHRs, obituaries, and Social Security Death Index) and unstructured EHR data (abstracted) were linked to generate a composite mortality variable. Study design We benchmarked sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and ±15‐day agreement against the National Death Index (NDI). Real‐world overall survival (rwOS) was estimated using the Kaplan‐Meier method. We performed sensitivity analyses using a smaller patient cohort that underwent next‐generation sequencing testing. Principal findings Compared with the NDI across 18 cancer types (overall N = 160 436): sensitivity, 83.9%‐91.5% (17/18 cancer types had sensitivity ≥85.0%); specificity, 93.5%‐99.7%; PPV, 96.3%‐98.3%; NPV, 75.0%‐98.7%; ±15‐day agreement, 95.6%‐97.6%; and median rwOS estimates ranging from 2.8% to 12.7% greater. Sensitivity analysis results (n = 17 540) were consistent with the main analysis. Conclusions Across all cancer types analyzed, this composite mortality variable showed high sensitivity, specificity, PPV, NPV, and ±15‐day agreement, and yielded median rwOS values modestly overestimated when compared to NDI‐based results.

Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data

“…For censoring, the last confirmed activity date (i.e., last structured visit or last oral cancer drug episode from unstructured data) was used. Dates of death were based on a composite mortality variable [ 9 ].…”

Natural History of Human Epidermal Growth Factor Receptor 2–Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice

“…Date of death was a composite end point on the basis of mortality data curated from structured and unstructured information in the EHRs (eg, clinician notes), obituary records, or the Social Security Death Index. 15 …”

Accounting for Delayed Entry in Analyses of Overall Survival in Clinico-Genomic Databases

“…NGS testing dates were abstracted along (20). Death dates were determined via a previously described mortality variable (21). Patients are considered ALK positive (ALK+) or EGFR positive (EGFR+) if they have a positive result any time before the advanced NSCLC diagnosis date plus 60 days.…”